I2 therapeutics: business plan

Abstract

Cancer is a leading cause of death world wide. Although Big Pharma companies spend millions in R&D, their effectiveness leaves much to be desired. “I2 Therapeutics” is our biotech start up that addresses this with a novel targeted drug delivery platform called Syderum. The scope of this project was to build an entrepreneurial business model based on science .Our result is a B2B framework that focusses on improving block buster drugs through licensing. Our ambition is to persuade pharma companies to ameliorate cancer therapeutics. By reducing treatments cycles, helping overwhelmed health care systems we aim the best impact. There fore, this company could improve economic and social conditions in the communities.